AMENDMENT TO THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims

1-11. **(Canceled)**

12. **(Currently amended)** A therapeutic method for a cancer, comprising administering to a patient suffering from a cancer ~~expressing excessive c-Kit kinase or a mutant c-Kit kinase~~, a pharmacologically effective dose of ~~the c-Kit kinase inhibitor according to claim 1.~~ a compound represented by the general formula (I), a salt thereof or a hydrate of the foregoing:



(I)

wherein R^1 represents methyl, 2-methoxyethyl or a group represented by the formula (II):



(II)

wherein R^{a3} represents methyl, cyclopropylmethyl or cyanomethyl; R^{a1} represents hydrogen, fluorine or hydroxyl; and R^{a2} represents 1-pyrrolydinyl, 1-piperidinyl, 4-morpholinyl, dimethylamino or diethylamino;

R^2 represents cyano or $-CONHR^{a4}$ wherein R^{a4} represents hydrogen, C_{1-6} alkyl, C_{3-8} cycloalkyl, C_{1-6} alkoxy or C_{3-8} cycloalkoxy;

R^3 represents hydrogen, methyl, trifluoromethyl, chlorine or fluorine; and

R^4 represents hydrogen, methyl, ethyl, n-propyl, cyclopropyl, 2-thiazolyl or 4-fluorophenyl,

wherein the cancer is acute myelogenous leukemia, mast cell leukemia, small cell lung cancer, gastrointestinal stromal tumors, testicular cancer, ovarian cancer, breast cancer, brain cancer, neuroblastoma or colorectal cancer.

13. **(Canceled)**

14. **(Currently amended)** The method according to claim 12, wherein the cancer ~~expressing excessive c-Kit kinase or a mutant c-Kit kinase~~ is acute myelogenous leukemia, a small cell lung cancer or GIST.

15. **(Currently amended)** A therapeutic method for a cancer, comprising the steps of:

extracting cancer cells from a patient suffering from a cancer;

confirming that the cancer cells are expressing excessive c-Kit kinase or a mutant c-Kit kinase; and

administering to the patient a pharmacologically effective dose of ~~the c-Kit kinase inhibitor according to claim 1.~~ a compound represented by the general formula (I), a salt thereof or a hydrate of the foregoing:



(I)

wherein R^1 represents methyl, 2-methoxyethyl or a group represented by the formula (II):



wherein R^{a3} represents methyl, cyclopropylmethyl or cyanomethyl; R^{a1} represents hydrogen, fluorine or hydroxyl; and R^{a2} represents 1-pyrrolydinyl, 1-piperidinyl, 4-morpholinyl, dimethylamino or diethylamino;

R^2 represents cyano or -$CONHR^{a4}$ wherein R^{a4} represents hydrogen, C_{1-6} alkyl, C_{3-8} cycloalkyl, C_{1-6} alkoxy or C_{3-8} cycloalkoxy;

R^3 represents hydrogen, methyl, trifluoromethyl, chlorine or fluorine; and

R^4 represents hydrogen, methyl, ethyl, n-propyl, cyclopropyl, 2-thiazolyl or 4-fluorophenyl,

wherein the cancer is acute myelogenous leukemia, mast cell leukemia, small cell lung cancer, gastrointestinal stromal tumors, testicular cancer, ovarian cancer, breast cancer, brain cancer, neuroblastoma or colorectal cancer.

16. **(Currently amended)** A therapeutic method for mastocytosis, allergy or asthma, comprising administering to a patient suffering from the disease, a pharmacologically effective dose of ~~the c-Kit kinase inhibitor according to claim 1.~~ a compound represented by the general formula (I), a salt thereof or a hydrate of the foregoing:



wherein R^1 represents methyl, 2-methoxyethyl or a group represented by the formula (II):



(II)

wherein R^{a3} represents methyl, cyclopropylmethyl or cyanomethyl; R^{a1} represents hydrogen, fluorine or hydroxyl; and R^{a2} represents 1-pyrrolydinyl, 1-piperidinyl, 4-morpholinyl, dimethylamino or diethylamino;

R^2 represents cyano or -$CONHR^{a4}$ wherein R^{a4} represents hydrogen, C_{1-6} alkyl, C_{3-8} cycloalkyl, C_{1-6} alkoxy or C_{3-8} cycloalkoxy;

R^3 represents hydrogen, methyl, trifluoromethyl, chlorine or fluorine; and

R^4 represents hydrogen, methyl, ethyl, n-propyl, cyclopropyl, 2-thiazolyl or 4-fluorophenyl.

17. **(Currently amended)** A method ~~for inhibiting the c-Kit kinase activity,~~ comprising applying to a cell expressing excessive c-Kit kinase or a mutant c-Kit kinase, a pharmacologically effective dose of ~~the c-Kit kinase inhibitor according to claim 1.~~ a compound represented by the general formula (I), a salt thereof or a hydrate of the foregoing:



(I)

wherein R^1 represents methyl, 2-methoxyethyl or a group represented by the formula (II):



wherein R^{a3} represents methyl, cyclopropylmethyl or cyanomethyl; R^{a1} represents hydrogen, fluorine or hydroxyl; and R^{a2} represents 1-pyrrolydinyl, 1-piperidinyl, 4-morpholinyl, dimethylamino or diethylamino;

R^2 represents cyano or -$CONHR^{a4}$ wherein R^{a4} represents hydrogen, C_{1-6} alkyl, C_{3-8} cycloalkyl, C_{1-6} alkoxy or C_{3-8} cycloalkoxy;

R^3 represents hydrogen, methyl, trifluoromethyl, chlorine or fluorine; and

R^4 represents hydrogen, methyl, ethyl, n-propyl, cyclopropyl, 2-thiazolyl or 4-fluorophenyl.

18. **(Original)** The method according to claim 12, wherein the compound represented by the formula(I) is 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide.

19. **(Original)** The method according to claim 15, wherein the compound represented by the formula(I) is 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide.

20. **(Original)** The method according to claim 17, wherein the compound represented by the formula(I) is 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide.